ORION OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36 EUR | +0.84% |
|
-0.14% | -8.16% |
| 04-26 | Orion Corporation Announces Appointments to Nomination Committee | CI |
| 04-25 | Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024 |
| Sales 2024 * | 1.38B 1.48B 2.03B | Sales 2025 * | 1.45B 1.56B 2.14B | Capitalization | 5.07B 5.46B 7.47B |
|---|---|---|---|---|---|
| Net income 2024 * | 242M 260M 356M | Net income 2025 * | 250M 269M 368M | EV / Sales 2024 * | 3.65 x |
| Net cash position 2024 * | 46.22M 49.74M 68.06M | Net cash position 2025 * | 3.2M 3.44M 4.71M | EV / Sales 2025 * | 3.49 x |
| P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
20.3
x | Employees | 3,698 |
| Yield 2024 * |
4.64% | Yield 2025 * |
4.73% | Free-Float | 88.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | +0.84% | ||
| 1 week | -0.14% | ||
| Current month | -0.28% | ||
| 1 month | +7.78% | ||
| 3 months | -14.49% | ||
| 6 months | -1.91% | ||
| Current year | -8.16% |
1 week
35.45
36.65
1 month
32.5036.65
Current year
32.5045.15
1 year
32.5045.15
3 years
32.5055.00
5 years
28.2055.00
10 years
21.5558.35
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Chief Operating Officer | - | 15-12-31 | |
Outi Vaarala
CTO | Chief Tech/Sci/R&D Officer | 62 | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 36 | +0.84% | 5,547 |
| 24-05-02 | 35.7 | -1.11% | 2,988 |
| 24-04-30 | 36.1 | -1.37% | 5,972 |
| 24-04-29 | 36.6 | +1.53% | 10,096 |
| 24-04-26 | 36.05 | +1.69% | 13,144 |
Delayed Quote Nasdaq Helsinki, May 03, 2024 at 11:29 am
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
36.12
EUR
Average target price
39
EUR
Spread / Average Target
+7.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- ORNBV Stock
- ORNAV Stock
